Research Grant
[Cite as http://purl.org/au-research/grants/arc/LP140100142]Researchers: Dr Thomas Barclay (Chief Investigator) , Sanjay Garg (Chief Investigator) , Dr Peter Cooper (Partner Investigator) , Nikolai Petrovsky (Partner Investigator)
Brief description Drug Targeting to Immune Cells Using Modified Inulin Particles. Vaxine Pty Ltd is an Australian biotechnology company that has discovered specific particulate forms of inulin that are efficiently internalised by human immune cells. This project aims to exploit cell migration to injury and infection sites by attaching drugs to inulin particles creating a targeted drug delivery system. This system will transport drugs specifically to afflicted areas, reducing systemic concentrations of drugs and hence the risks of dose related side effects. This project has potential both to improve healthcare and to encourage the growth of expertise in the biotechnology industry in Australia.
Funding Amount $330,000
Funding Scheme Linkage Projects
- ARC : LP140100142
- PURL : http://purl.org/au-research/grants/arc/LP140100142
